WO2005119263A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) - Google Patents
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) Download PDFInfo
- Publication number
- WO2005119263A3 WO2005119263A3 PCT/EP2005/005788 EP2005005788W WO2005119263A3 WO 2005119263 A3 WO2005119263 A3 WO 2005119263A3 EP 2005005788 W EP2005005788 W EP 2005005788W WO 2005119263 A3 WO2005119263 A3 WO 2005119263A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- gpr92
- therapeutics
- diagnostics
- protein
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 9
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 title abstract 2
- 101710149747 Lysophosphatidic acid receptor 5 Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000057650 human LPAR5 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a human GPR92 which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR92 as well as pharmaceutical compositions comprising such compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04013106.2 | 2004-06-03 | ||
| EP04013106 | 2004-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005119263A2 WO2005119263A2 (en) | 2005-12-15 |
| WO2005119263A3 true WO2005119263A3 (en) | 2006-02-16 |
Family
ID=34969026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/005788 WO2005119263A2 (en) | 2004-06-03 | 2005-05-30 | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005119263A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3442992B1 (en) * | 2016-04-14 | 2024-04-10 | Mars, Incorporated | Methods for identifying modulators of gpr92 |
| WO2020051551A1 (en) | 2018-09-07 | 2020-03-12 | Mars, Incorporated | Compounds that modulate gpr92 receptor activity and pet food products containing the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001087937A2 (en) * | 2000-05-18 | 2001-11-22 | Incyte Genomics, Inc. | G-protein coupled receptors |
-
2005
- 2005-05-30 WO PCT/EP2005/005788 patent/WO2005119263A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001087937A2 (en) * | 2000-05-18 | 2001-11-22 | Incyte Genomics, Inc. | G-protein coupled receptors |
Non-Patent Citations (2)
| Title |
|---|
| LEE D K ET AL: "Discovery and mapping of ten novel G protein-coupled receptor genes", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 275, no. 1, 5 September 2001 (2001-09-05), pages 83 - 91, XP004307114, ISSN: 0378-1119 * |
| TAO YA-XIONG ET AL: "Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor.", 13 February 2004, THE JOURNAL OF BIOLOGICAL CHEMISTRY. 13 FEB 2004, VOL. 279, NR. 7, PAGE(S) 5904 - 5914, ISSN: 0021-9258, XP009054365 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005119263A2 (en) | 2005-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (en) | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) | |
| WO2005093092A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) | |
| WO2005106012A3 (en) | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) | |
| WO2006010517A3 (en) | Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap) | |
| WO2006005469A3 (en) | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) | |
| WO2005100990A3 (en) | Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) | |
| WO2005103684A3 (en) | Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) | |
| WO2005106491A3 (en) | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) | |
| WO2005031345A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2) | |
| WO2005119263A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) | |
| WO2005076007A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12) | |
| WO2005101001A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c) | |
| WO2006021343A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a) | |
| WO2005073729A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11) | |
| WO2005113788A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6) | |
| WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
| WO2006005461A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27) | |
| WO2005075983A3 (en) | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3) | |
| WO2005113786A3 (en) | Diagnostics and therapeutics for diseases associated with chymase (cma1) | |
| WO2005106486A3 (en) | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) | |
| WO2005101011A3 (en) | Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra) | |
| WO2005114210A8 (en) | Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3) | |
| WO2005100997A3 (en) | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) | |
| WO2006005470A3 (en) | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) | |
| WO2006008003A3 (en) | Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |